- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute coronary syndrome
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 359KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 51KB)
Ticagrelor – March 2023
Ticagrelor: Tablet, 90 mg; Brilinta®
Last updated
14 July 2023